Connect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy

🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.✅ Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.✅ CNTB’s strong cash position ($71.8M) and runway into 2027, fully funding its U.S.-focused clinical milestones.✅ How its proven management team — responsible for bringing 16 drugs to FDA approval — is positioning the company for long-term growth.🎬 Watch now to learn why Connect Biopharma could be one of the most compelling small-cap biotech opportunities heading into 2026.Connect Biopharma is a client of RedChip. To learn more about CNTB and to read our full disclosure, visit: CNTBinfo.com.#CNTB #BiotechStocks #SmallCapStocks #AsthmaTreatment #COPD #HealthcareInnovation #Investing #BiotechInvesting #ClinicalTrials #NASDAQ